[Click eStock] "Zencurix's Breast Cancer Prognosis Test... Will Become Asia's Leading Diagnostic"
[Asia Economy Reporter Hyunseok Yoo] Heungkuk Securities analyzed on the 24th that GenCurix's breast cancer prognosis diagnostic test will grow into a diagnostic test representing Asia. No investment opinion or target price was presented.
GenCurix is a molecular diagnostics specialized company providing breast cancer prognosis diagnosis, lung cancer and colorectal cancer companion diagnosis, and early diagnosis solutions for colorectal cancer and liver cancer. The company's breast cancer prognosis diagnostic test (GenesWell BCT) is a diagnostic test that selects low-risk patients who have a low risk of recurrence after resection surgery and do not require chemotherapy.
Choi Jong-kyung, a researcher at Heungkuk Securities, said, "GenCurix's prognosis prediction test holds a definite comparative advantage, including being the only test approved by the Ministry of Food and Drug Safety in Korea, the world's only clinical efficacy verification targeting Asians, and price competitiveness with a price below 3 million KRW compared to competing products priced around 4 million KRW, with reimbursement insurance available." He added, "It is expected that rapid market share expansion in Korea will be possible in the future."
He explained, "It is expected to grow not only domestically but also as a diagnostic test representing Asia, including Japan and China," and "It is known that positive usage plans are currently being discussed with major large hospitals in Korea since the approval of innovative medical technology last October."
Hot Picks Today
"Most Americans Didn't Want This"... Americans Lose 60 Trillion Won to Soaring Fuel Costs
- "Striking Will Lead to Regret": Hyundai-Kia Employees Speak Out... Uneasy Stares Toward Samsung Union
- Man in His 50s Arrested for Confining Girlfriend in Car After She Announced Breakup
- Assaulted by Elementary Student During Class... No Protection Due to 'Instructor' Status
- "If You Booked This Month, You Almost Lost Out... Why You Should Wait Until 'This Day' Before Paying for Flight Tickets"
Researcher Choi advises that the continued positive outlook after listing is an investment point. He emphasized, "The approval of innovative medical technology for the breast cancer prognosis diagnostic test in October, and the new listing of NgenBio, jointly invested with KT in December, are major investment points following the listing on the KOSDAQ market."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
